ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with CAD.
CARDINAL was an open-label (meaning everyone knew what drug they were given), 6-month clinical study in 24 patients with a recent history* of blood transfusions.
*Patients received at least 1 blood transfusion during the 6 months prior to starting the study.
The proportion of patients who experienced all of the following:
Increases in hemoglobin levels from the start of the study (increase ≥ 2 g/dL or Hb ≥ 12 g/dL at treatment assessment†)
No blood transfusions from Week 5 through Week 26 of the study
No treatment for CAD beyond what was permitted per protocol from Week 5 through Week 26
A primary outcome is the main result measured at the end of the study to see if a given treatment worked.
†Defined as the mean value from Weeks 23, 25 and 26.
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
*Events may be counted in more than one grouped term, e.g., viral upper respiratory tract infection is counted in viral infection and respiratory tract infection.
Whether you're taking ENJAYMO or interested in learning more, sign up to receive additional information, resources, and helpful tools to support you on your journey with Cold Agglutinin Disease.
Sign Up NowENJAYMO is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with Cold Agglutinin Disease (CAD). It is not known if ENJAYMO is safe and effective in children.
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:
The most common side effects of ENJAYMO include:
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see Full Prescribing Information, including Medication Guide.
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).
It is not known if ENJAYMO is safe and effective in children.
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:
The most common side effects of ENJAYMO include:
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see Full Prescribing Information, including Medication Guide.